New hope for elderly and genetically High-Risk CLL patients
NCT ID NCT01500733
First seen May 01, 2026 · Last updated May 24, 2026 · Updated 6 times
Summary
This study tests a daily pill called PCI-32765 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are over 65 or have a specific genetic change (17p deletion). These groups often don't respond well to standard chemotherapy. The goal is to see if the drug can shrink or control the cancer safely. Participants take the drug for 28-day cycles and may continue if it helps.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.